This website is intended for U.S. Healthcare Professionals.
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Resources for healthcare professionals and patients
Here, you can access tools and other resources that you and your patients may find helpful for learning more about REVLIMID. Check back for updates as new resources become available.
Downloads.
Full Prescribing Information
Explore the full Prescribing Information, including Boxed WARNINGS.
DownloadResources for patients and caregivers.
This list of independent organizations is provided as an additional resource for obtaining information related to mantle cell lymphoma (MCL). Inclusion on this list does not indicate endorsement by Celgene Corporation, a Bristol Myers Squibb company, of an organization or its communications.
Patient support groups
American Cancer Society
www.cancer.org
(800-227-2345)
Leukemia & Lymphoma Society®
www.lls.org
(800-955-4572)
Lymphoma Research Foundation
www.lymphoma.org
(800-500-9976)
National Cancer Institute
www.cancer.gov
(800-4-CANCER) (800-422-6237)
Resources for caregivers
Association of Cancer Online Resources
www.acor.org
(212-226-5525)
CancerCare®
www.cancercare.org
(800-813-4673)
Family Caregiver Alliance®
www.caregiver.org
(800-445-8106)
National Alliance for Caregiving
www.caregiving.org
(online only)
National Coalition for Cancer Survivorship
www.canceradvocacy.org
(301-650-9127)
Caregiver Action Network
www.caregiveraction.org
(202-772-5050)
Well Spouse® Association
www.wellspouse.org
